Analysts see upside, diversification potential in Eu1bn Aventis bond
Aventis will offer investors a rare opportunity to gain exposure to the pharmaceuticals sector in the coming weeks when it launches a Eu1bn five year benchmark via Credit Suisse First Boston, Dresdner Kleinwort Wasserstein and SG.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: